Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer

• Status: Terminated
• Trial end date: 2013-08-01

Summary

RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).

PURPOSE: This phase I trial is studying the safety of donor umbilical cord blood transplant after fludarabine phosphate, cyclophosphamide, and total-body irradiation in treating patients with high-risk hematologic cancer (now closed).

The Phase II part of this trial is studying whether priming one of two UCB units with C3a facilitates engraftment of the treated unit.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Masonic Cancer Center, University of Minnesota
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Complement C3a; Complement System Proteins; Cyclophosphamide; Fludarabine; Fludarabine phosphate; Vidarabine